“…Specifically, its generalizability to patients with unique presentations (e.g., psychiatric inpatients; patients undergoing chemotherapy; patients with dementia, chronic pain, sports concussion, or limited English proficiency) must be established before the V-5 can be recommended for widespread use. Neuropsychiatric constructs have been reported to vary across assessment settings (Abeare, Messa, et al, 2019; An, Kaploun, Erdodi, & Abeare, 2017, 2019; Bailey, Soble, & O’Rourke, 2018; Erdodi & Lichtenstein, 2017; Glassmire et al, 2019; Poynter et al, 2019; Roye, Calamia, Bernstein, De Vito, & Hill, 2019) and locations (Eglit et al, 2019; Erdodi, Abeare, et al, 2018; Lichtenstein et al, 2019). Therefore, readers are reminded that the V-5 is currently at an early stage of validation and is awaiting independent replication.…”